Molecular and Cellular Biomedical Sciences: MCBS | |
Allogeneic Mesenchymal Stem Cells and Its Conditioned Medium as a Potential Adjuvant Therapy for COVID-19 | |
article | |
Wahyu Widowati1  Ahmad Faried2  Hanna Sari Widya Kusuma3  Yulius Hermanto2  Ali Budi Harsono4  Tono Djuwantono4  | |
[1] Faculty of Medicine, Maranatha Christian University;Department of Neurosurgery, Faculty of Medicine, Universitas Padjadjaran/Dr. Hasan Sadikin Hospital;Biomolecular and Biomedical Research Center;Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran/Dr. Hasan Sadikin Hospital | |
关键词: adjuvant therapy; COVID-19; mesenchymal stem cells; secretome; | |
DOI : 10.21705/mcbs.v7i1.287 | |
来源: Cell and BioPharmaceutical Institute | |
【 摘 要 】
Recent research has demonstrated that mesenchymal stem cells (MSCs) potentially benefit and enhance coronavirus disease (COVID-19) recovery. This benefit occurs via a mechanism that promotes viral clearance by phagocytes and macrophages. This action occurs through the innate (increase in IL-10 production and decrease in TNF-α and IL-12 production) and the adaptive immune system (decrease in IL-17 production, promote regulatory T cell proliferation and inhibit effectors T cell proliferation). MSCs are expected to act as an anti-inflammatory in the hyper-inflammatory state of COVID-19. MSCs enhance immune cell replacement that have been overwhelmed or have been lost due to cytokine storm. Although vaccines are the answer to this pandemic, MSCs can improve COVID-19 patients, especially in patients with chronic illnesses. The focus on keeping death-rates low is a great opportunity for MSCs-based therapy for severe or critically ill patients. MSCs and conditioned medium have the potential to serve as adjunctive therapy in preventing the body's overactive defense response or the so-called cytokine storm caused by COVID-19.
【 授权许可】
Unknown
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202307110004597ZK.pdf | 1057KB | download |